Home / Health / Medicare Drug Plan Premiums to Rise as Subsidies End
Medicare Drug Plan Premiums to Rise as Subsidies End
30 Jul
Summary
- Medicare Part D subsidies ending at the close of 2026.
- Program cost $9.8 billion over two years for stabilization.
- Premiums may increase by less than $10 for most recipients.
Approximately 25 million Americans relying on standalone Medicare Part D drug plans are set to see adjustments in their monthly costs. The Centers for Medicare & Medicaid Services (CMS) announced the conclusion of the Part D Premium Stabilization Demonstration at the end of 2026. This temporary subsidy program, initiated in 2025, aimed to shield beneficiaries from substantial premium hikes.
Initially, the program reduced premiums by up to $15 monthly in 2025 and capped annual increases at $35. These figures were adjusted in 2026 to a $10 discount and a $50 cap. The program's objective was to allow insurance companies sufficient time to adapt to legislative changes affecting Medicare drug benefits. The total cost for this two-year initiative reached $9.8 billion.
CMS Administrator Dr. Mehmet Oz asserted that the subsidies were no longer necessary, stating the market is now stable. While some beneficiaries may see a slight increase of less than $10 per month, many could experience lower premiums. The baseline premium for calculations will rise to $296.05 in 2027, and the beneficiary starting premium will increase to $41.33. A separate law continues to limit annual increases in this base amount to 6% through 2029.
